Cochlear’s VA Nexa Rollout Sparks Fresh Look At Whether The Shares Are Undervalued

Simply Wall St.

Jan 15

AdvertisementCochlear’s VA access expansion and what it might mean for shareholders Cochlear (ASX:COH) recently made its Nucleus Nexa cochlear implant system available to eligible US military veterans...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2603606575"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2603606575\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2603606575?lang=en_US&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/industry/6021000-choice1-main-header/1585186659638","is_english":true,"pubTime":"2026-01-15 16:25","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2603606575","market":"hk","top_or_hot":-1,"title":"Cochlear’s VA Nexa Rollout Sparks Fresh Look At Whether The Shares Are Undervalued","media":"Simply Wall St.","content":"<div>\n<p>AdvertisementCochlear’s VA access expansion and what it might mean for shareholders Cochlear (ASX:COH) recently made its Nucleus Nexa cochlear implant system available to eligible US military veterans...</p>\n\n<a href=\"https://simplywall.st/stocks/au/healthcare/asx-coh/cochlear-shares/news/cochlears-va-nexa-rollout-sparks-fresh-look-at-whether-the-s\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Cochlear’s VA Nexa Rollout Sparks Fresh Look At Whether The Shares Are Undervalued</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCochlear’s VA Nexa Rollout Sparks Fresh Look At Whether The Shares Are Undervalued\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-01-15 16:25 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/au/healthcare/asx-coh/cochlear-shares/news/cochlears-va-nexa-rollout-sparks-fresh-look-at-whether-the-s><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>AdvertisementCochlear’s VA access expansion and what it might mean for shareholders Cochlear (ASX:COH) recently made its Nucleus Nexa cochlear implant system available to eligible US military veterans...</p>\n\n<a href=\"https://simplywall.st/stocks/au/healthcare/asx-coh/cochlear-shares/news/cochlears-va-nexa-rollout-sparks-fresh-look-at-whether-the-s\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK7007","symbol_name":"医疗保健设备","start_time":0,"source_url":"https://simplywall.st/stocks/au/healthcare/asx-coh/cochlear-shares/news/cochlears-va-nexa-rollout-sparks-fresh-look-at-whether-the-s","article_id":"2603606575","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/industry/6021000-choice1-main-header/1585186659638"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/au/healthcare/asx-coh/cochlear-shares/news/cochlears-va-nexa-rollout-sparks-fresh-look-at-whether-the-s","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2603606575","pubTimestamp":1768465515,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"Cochlear’s VA access expansion and what it might mean for shareholders\nCochlear (ASX:COH) recently made its Nucleus Nexa cochlear implant system available to eligible US military veterans at VA clinics nationwide, a move that widens access and puts a spotlight on its hearing technology offering.\nSee our latest analysis for Cochlear.\nThe Nucleus Nexa news comes after a period where short term share price momentum has softened. A 90 day share price return of a 6.38% decline contrasts with a 5...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK7007":"医疗保健设备","COH.AU":"COCHLEAR LTD"},"translate_title":"耳蜗VA Nexa的推出引发了人们对该股是否被低估的重新审视","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"COH.AU":1.5},"content_text":"AdvertisementCochlear’s VA access expansion and what it might mean for shareholders Cochlear (ASX:COH) recently made its Nucleus Nexa cochlear implant system available to eligible US military veterans at VA clinics nationwide, a move that widens access and puts a spotlight on its hearing technology offering. See our latest analysis for Cochlear. The Nucleus Nexa news comes after a period where short term share price momentum has softened. A 90 day share price return of a 6.38% decline contrasts with a 5 year total shareholder return of 45.48%, suggesting long term holders have still seen meaningful gains even as recent sentiment has cooled. If Cochlear’s VA rollout has you thinking about other specialist healthcare names, it could be a useful moment to scan healthcare stocks for more ideas in the sector. With shares around A$267.41, a recent 1 year total return decline of 10.65% and a 5 year total return of 45.48%, the real question is whether Cochlear is quietly undervalued today or if the market is already pricing in future growth. Most Popular Narrative: 12.4% Undervalued Compared with Cochlear’s last close at A$267.41, the most followed narrative pegs fair value materially higher at A$305.38, using a 7.05% discount rate and long term earnings assumptions. The launch of the Nexa system, the world's first smart cochlear implant, is expected to drive market share gains in developed markets due to strong differentiation, surgeon enthusiasm, and planned price increases, likely boosting revenue and average selling prices (ASPs) starting in 2H FY26. Read the complete narrative. Curious what kind of revenue trajectory, margin lift and future P/E multiple need to come together to justify that higher fair value line? The core assumptions sit inside this narrative, along with how far earnings might need to stretch to make the numbers balance. Result: Fair Value of $305.38 (UNDERVALUED) Have a read of the narrative in full and understand what's behind the forecasts. However, this hinges on assumptions that could be challenged if pricing pressure in China intensifies or if Western Europe implant demand remains soft for a longer period. Find out about the key risks to this Cochlear narrative. Another way to look at Cochlear’s valuation The popular narrative suggests Cochlear is 12.4% undervalued at A$267.41 versus fair value of A$305.38. Our SWS DCF model points in the opposite direction, with fair value at A$190.67. This would imply the shares are trading at a premium instead. Which story do you lean toward? Look into how the SWS DCF model arrives at its fair value. COH Discounted Cash Flow as at Jan 2026 Build Your Own Cochlear Narrative If you see the numbers differently or want to stress test your own assumptions, you can build a custom Cochlear story in just a few minutes: Do it your way. A good starting point is our analysis highlighting 2 key rewards investors are optimistic about regarding Cochlear. Looking for more investment ideas? If Cochlear has sparked your thinking, do not stop here. The market is full of other angles that could fit your style and time horizon.  Spot under-the-radar value by scanning these 878 undervalued stocks based on cash flows that might not be on everyone else’s watchlist yet. Target future growth themes with these 25 AI penny stocks related to the expansion of artificial intelligence across multiple industries. Focus on higher income potential through these 12 dividend stocks with yields > 3% that offer yields above 3% for a stronger cash return profile.   This article by Simply Wall St is general in nature. We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.New: AI Stock Screener & AlertsOur new AI Stock Screener scans the market every day to uncover opportunities.• Dividend Powerhouses (3%+ Yield)• Undervalued Small Caps with Insider Buying• High growth Tech and AI CompaniesOr build your own from over 50 metrics.Explore Now for FreeHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}